Last quarter (Q2 2018), ImmunoCellular Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, ImmunoCellular Therapeutics's net income was $-306.70K. See ImmunoCellular Therapeutics’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 17	Dec 16	Dec 15	Dec 14	Dec 13
Total Revenue	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	$ 0.00	$ 0.00
Gross Profit	-	-	-	-	$ 0.00	$ 0.00
Operating Expense	$ 5.66M	$ 21.15M	$ 24.11M	$ 15.51M	$ 9.86M	$ 9.46M
Operating Income	$ -5.66M	$ -21.15M	$ -24.11M	$ -15.51M	$ -9.86M	$ -9.46M
Net Non Operating Interest Income Expense	$ 1.11K	$ -878.00K	$ -1.79M	$ -202.98K	$ -48.77K	$ 17.34K
Other Income Expense	-	$ 7.72M	$ 3.81M	$ 2.93M	$ 529.77K	$ 642.41K
Pretax Income	$ -5.66M	$ -14.31M	$ -22.09M	$ -12.79M	$ -9.38M	$ -8.80M
Tax Provision	-	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -9.03M	$ -17.68M	$ -22.09M	$ -12.79M	$ -9.38M	$ -8.80M
Basic EPS	$ -4.69	$ -12.30	$ -78.90	$ -60.00	$ -64.00	$ -64.00
Diluted EPS	$ -4.73	$ -12.30	$ -78.91	$ -60.00	$ -64.00	$ -64.00
Basic Average Shares	$ 14.11M	$ 1.44M	$ 279.89K	$ 218.01K	$ 149.79K	$ 135.70K
Diluted Average Shares	$ 14.11M	$ 1.44M	$ 279.89K	$ 218.01K	$ 149.79K	$ 135.70K
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 5.66M	$ 21.15M	$ 24.11M	$ 15.51M	$ 9.86M	$ 9.46M
Net Income From Continuing And Discontinued Operation	$ -5.66M	$ -14.31M	$ -22.09M	$ -12.79M	$ -9.38M	$ -8.80M
Normalized Income	$ -5.66M	$ -14.31M	$ -25.90M	$ -15.72M	$ -9.91M	$ -9.44M
Interest Expense	-	$ 882.68K	$ 1.31M	$ 133.91K	$ 0.00	$ 0.00
EBIT	$ -5.66M	$ -13.43M	$ -20.77M	$ -12.66M	$ -9.38M	$ -9.46M
EBITDA	$ -5.65M	$ -13.38M	$ -20.70M	$ -12.62M	$ -9.33M	$ -9.41M

Currency in USD

ImmunoCellular Therapeutics Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing